Immatics (NASDAQ:IMTXW) Short Interest Update

Immatics (NASDAQ:IMTXW) was the recipient of a large drop in short interest in the month of September. As of September 30th, there was short interest totalling 1,300 shares, a drop of 13.3% from the September 15th total of 1,500 shares. Based on an average trading volume of 800 shares, the short-interest ratio is currently 1.6 days.

Immatics Price Performance

NASDAQ IMTXW traded up $0.05 on Wednesday, hitting $1.21. The company had a trading volume of 800 shares, compared to its average volume of 8,121. The company’s fifty day moving average price is $2.36 and its 200-day moving average price is $2.68. Immatics has a 12-month low of $0.87 and a 12-month high of $4.14.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.